BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to H460 cell line is 452
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by Western Blotting and RT-PCR | NA | 0.6 | 0.684 | 28931539 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and IF staining | NA | 0.6 | 0.684 | 25411331 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.6 | 0.684 | 28861158 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA and ALDEFLUOR assay followed by Western Blotting | NA | 0.6 | 0.684 | 34163000 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs and Western Blotting | NA | 0.6 | 0.684 | 30737252 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.6 | 0.684 | 34832867 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 34195288 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 26339272 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Ciprofloxacin | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 26947806 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 28122729 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 28179308 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 28259926 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 28677037 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 28931539 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 30111255 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 31100681 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 32509180 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by FACs | NA | 0.6 | 0.684 | 19276181 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by FACs | NA | 0.6 | 0.684 | 24595209 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by FACs and CFA | NA | 0.6 | 0.684 | 27542268 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and SFA | NA | 0.6 | 0.684 | 34246759 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | ALDEFLUOR assay followed by CFA | NA | 0.6 | 0.684 | 33550205 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | ALDEFLUOR assay | NA | 0.6 | 0.684 | 23349823 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by Migration assay | NA | 0.6 | 0.684 | 19276181 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Paclitaxel | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 24278179 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 24309934 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 28797843 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | CFA and SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28406482 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by Tumorigenicity assay | NA | 0.6 | 0.684 | 21827695 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 25276790 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28850563 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Sorafenib | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28850563 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 31466290 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.684 | 22592563 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by Western Blotting and RT-PCR | NA | 0.6 | 0.7582 | 28931539 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting followed by IF staining | NA | 0.6 | 0.7582 | 34832867 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and IF staining | NA | 0.6 | 0.7582 | 25411331 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | MACs and FACs followed by qRT-PCR | NA | 0.6 | 0.7582 | 28619508 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by Western Blotting | NA | 0.6 | 0.7582 | 31074646 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs and Western Blotting | NA | 0.6 | 0.7582 | 30737252 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by IF staining | NA | 0.6 | 0.7582 | 19276181 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | 5-fluorouracil | FACs followed by qRT-PCR | NA | 0.6 | 0.7582 | 22416214 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Methotrexate | FACs followed by qRT-PCR | NA | 0.6 | 0.7582 | 22416214 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.6 | 0.7582 | 34635641 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 34195288 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 26339272 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Ciprofloxacin | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 26947806 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 28122729 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 28179308 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 28259926 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 28677037 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 28931539 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 30111255 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 31100681 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 32782570 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and SP assay | NA | 0.6 | 0.7582 | 26911281 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | Western Blotting | NA | 0.6 | 0.7582 | 30341415 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Doxorubicin+Cisplatin+Etiopside | SP assay and SFA followed by IF staining and Tumorigenicity assay | NA | 0.6 | 0.7582 | 18728788 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs for CSC marker followed by qRT-PCR | NA | 0.6 | 0.7582 | 33550205 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and SFA | NA | 0.6 | 0.7582 | 34246759 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.6 | 0.7582 | 24961511 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR | NA | 0.6 | 0.7582 | 22552503 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.6 | 0.7582 | 24961511 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by qRT-PCR | NA | 0.6 | 0.7582 | 27911857 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by RT-PCR | NA | 0.6 | 0.7582 | 22855139 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.6 | 0.7582 | 33068069 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs | NA | 0.6 | 0.7582 | 34827096 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs | NA | 0.6 | 0.7582 | 35337095 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs and SFA | NA | 0.6 | 0.7582 | 34063628 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 34044271 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 34349823 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 34424425 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by FACs | NA | 0.6 | 0.7582 | 35267489 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | CFA and SFA followed by FACs | NA | 0.6 | 0.7582 | 28406482 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs | NA | 0.6 | 0.7582 | 23349823 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs | NA | 0.6 | 0.7582 | 24595209 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | SAHA | FACs | NA | 0.6 | 0.7582 | 26839308 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 26901847 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31466290 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 20028869 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 20028869 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Taxol | SFA followed by FACs | NA | 0.6 | 0.7582 | 27281614 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 28580971 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting followed by IF staining | NA | 0.52 | 0.6448 | 34832867 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34063628 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28406482 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28861158 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.52 | 0.6448 | 34635641 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.52 | 0.6448 | 32637578 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 27281614 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 28677037 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 30111255 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 32509180 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.52 | 0.6448 | 26885450 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.52 | 0.6448 | 30305725 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Paclitaxel | SP assay followed by Western Blotting and Tumorigenicity assay | NA | 0.52 | 0.6448 | 23022172 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | Western Blotting | NA | 0.52 | 0.6448 | 23349823 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 26901847 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.52 | 0.6448 | 33068069 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs for CSC marker followed by qRT-PCR | NA | 0.52 | 0.6448 | 33550205 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34209829 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34349823 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Pemetrexed | qPCR | NA | 0.52 | 0.6448 | 26181204 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | RT-PCR | NA | 0.52 | 0.6448 | 22300949 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Sorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qPCR and Tumorigenicity assay | NA | 0.52 | 0.6448 | 30305725 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 25276790 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31397494 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31658996 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31717588 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 24309934 |
| SCD | 10571 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.48 | 0.0127 | 24961511 |
| SCD | 10571 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.48 | 0.0127 | 24961511 |
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0604 | 27706681 |
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by invasion assay and RT-PCR | NA | 0.48 | 0.0604 | 17510412 |
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.0604 | 22855139 |
| ABCC1 | 51 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0212 | 27706681 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 28861158 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.1739 | 27911857 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | Western Blotting and qRT-PCR | NA | 0.48 | 0.1739 | 25200103 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Ciprofloxacin | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 26947806 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 28259926 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 31100681 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and SP assay | NA | 0.48 | 0.1739 | 26911281 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.1739 | 33068069 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.48 | 0.1739 | 24961511 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.1739 | 24961511 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by invasion assay and RT-PCR | NA | 0.48 | 0.1739 | 17510412 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 22855139 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by Tumorigenicity assay and RT-PCR | NA | 0.48 | 0.1739 | 22428030 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by SP assay and FACs | NA | 0.48 | 0.1739 | 26387547 |
| APBB1 | 581 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | RT-PCR and Western Blotting followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0011 | 27836546 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Western Blotting followed by RT-PCR | NA | 0.48 | 1 | 28931539 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA and FACs followed by Western Blotting | NA | 0.48 | 1 | 34163000 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by SFA and Western Blotting | NA | 0.48 | 1 | 26901847 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs followed by Western Blotting | NA | 0.48 | 1 | 31074646 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.48 | 1 | 31781681 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.48 | 1 | 34635641 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 34195288 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 1 | 32637578 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Ciprofloxacin | SFA followed by Western Blotting | NA | 0.48 | 1 | 26947806 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28179308 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28677037 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28741092 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28931539 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 30111255 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 32782570 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 23947765 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and SFA | NA | 0.48 | 1 | 34246759 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 1 | 24961511 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.48 | 1 | 33068069 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs followed by CFA | NA | 0.48 | 1 | 33550205 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 35267489 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs | NA | 0.48 | 1 | 23349823 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs | NA | 0.48 | 1 | 24595209 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | SAHA | FACs | NA | 0.48 | 1 | 26839308 |
| GLI1 | 4317 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0308 | 34424425 |
| GLI1 | 4317 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Western Blotting followed by CFA and SFA | NA | 0.48 | 0.0308 | 32509180 |
| JARID2 | 6196 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | qRT-PCR and Western Blotting and SFA | NA | 0.48 | 0.0032 | 34246759 |
| LRP1 | 6692 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 27706681 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34063628 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28406482 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 34635641 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 34832867 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34195288 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 35267489 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.5461 | 32637578 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 27281614 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 28677037 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30111255 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 32782570 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5461 | 26885450 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5461 | 30305725 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | Western Blotting | NA | 0.48 | 0.5461 | 23349823 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 26901847 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.5461 | 33068069 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.5461 | 33550205 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34209829 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34349823 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Pemetrexed | qPCR | NA | 0.48 | 0.5461 | 26181204 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by and qRT-PCR | NA | 0.48 | 0.5461 | 29620443 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qPCR and Tumorigenicity assay | NA | 0.48 | 0.5461 | 30305725 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 25276790 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 28406482 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31397494 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31658996 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31717588 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 24309934 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.48 | 0.5461 | 34044271 |
| PHC3 | 15682 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0021 | 34424425 |
| SCD | 10571 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0127 | 24309934 |
| SCD | 10571 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and SFA | NA | 0.48 | 0.0127 | 31717588 |
| SCD | 10571 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0127 | 31397494 |
| SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0201 | 34424425 |
| SMO | 11119 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0212 | 34424425 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 34063628 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 28406482 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 34635641 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.5695 | 32637578 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 26880969 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5695 | 26885450 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5695 | 30305725 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | Western Blotting | NA | 0.48 | 0.5695 | 23349823 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 26901847 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs for CSC marker followed by qRT-PCR | NA | 0.48 | 0.5695 | 33550205 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | qRT-PCR and SFA | NA | 0.48 | 0.5695 | 34246759 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34209829 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34349823 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Pemetrexed | qPCR | NA | 0.48 | 0.5695 | 26181204 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Sorafenib | qRT-PCR and SFA | NA | 0.48 | 0.5695 | 28850563 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.48 | 0.5695 | 28850563 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.48 | 0.5695 | 28850563 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qPCR and Tumorigenicity assay | NA | 0.48 | 0.5695 | 30305725 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 31397494 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 31658996 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 31717588 |
| YAP1 | 16262 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0117 | 27911857 |
| MYH9 | 7579 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0064 | 34635641 |
| THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.36 | 0.0371 | 31781681 |
| MIR2861 | 38221 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs and qRT-PCR | NA | 0.32 | 0.0032 | 29620443 |
| SOD2 | 11180 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.28 | 0.0064 | 24961511 |
| SOD2 | 11180 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.28 | 0.0064 | 24961511 |
| SOD2 | 11180 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.28 | 0.0064 | 24961511 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 34195288 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.28 | 0.1135 | 32637578 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 30111255 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 32782570 |
| CAMK2G | 1463 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 34195288 |
| FOXM1 | 3818 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 30111255 |
| FOXM1 | 3818 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 32782570 |
| LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by CFA and Western Blotting | NA | 0.28 | 0.0753 | 32637578 |
| LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | qRT-PCR and SFA | NA | 0.28 | 0.0753 | 34246759 |
| PRDX2 | 9353 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | Western Blotting | NA | 0.28 | 0.0074 | 30341415 |
| PRKAA1 | 9376 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0011 | 34195288 |
| SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 35267489 |
| SOD2 | 11180 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0064 | 34195288 |
| SOX9 | 11204 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0244 | 31658996 |
| TSPYL5 | 29367 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Gefitinib | SFA and Western Blotting | NA | 0.28 | 0.0032 | 34163000 |
| VIM | 12692 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.017 | 35267489 |
| ADM | 259 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 24961511 |
| ADM | 259 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 24961511 |
| ADM | 259 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.24 | 0.0032 | 24961511 |
| AKAP12 | 370 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 24961511 |
| AKAP12 | 370 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 24961511 |
| AKAP12 | 370 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 24961511 |
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0498 | 24961511 |
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0498 | 24961511 |
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.24 | 0.0498 | 24961511 |
| CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0498 | 24961511 |
| EGR1 | 3238 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 24961511 |
| EGR1 | 3238 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0074 | 24961511 |
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 24961511 |
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.24 | 0.0074 | 24961511 |
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0074 | 24961511 |
| IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0074 | 24961511 |
| JUN | 6204 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 24961511 |
| JUN | 6204 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 24961511 |
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 24961511 |
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 24961511 |
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 24961511 |
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0042 | 24961511 |
| LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0042 | 24961511 |
| MALAT1 | 29665 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 24961511 |
| MALAT1 | 29665 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 24961511 |
| PTGS2 | 9605 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 24961511 |
| PTGS2 | 9605 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 24961511 |
| PTGS2 | 9605 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0064 | 24961511 |
| PTGS2 | 9605 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.24 | 0.0064 | 24961511 |
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by IF staining | NA | 0.24 | 0.0583 | 23947765 |
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.24 | 0.0583 | 33068069 |
| ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.24 | 0.0583 | 29187584 |
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.24 | 0.0498 | 33068069 |
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Doxorubicin+Cisplatin+Etiopside | SP assay and SFA followed by IF staining and Tumorigenicity assay | NA | 0.24 | 0.018 | 18728788 |
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.24 | 0.018 | 20028869 |
| KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.24 | 0.018 | 20028869 |
| ABCA2 | 32 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SP assay followed by invasion assay and RT-PCR | NA | 0.2 | 0.0021 | 17510412 |
| B4GALT1 | 924 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 31717588 |
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.456 | 24961511 |
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.456 | 24961511 |
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | SAHA | FACs | NA | 0.2 | 0.456 | 26839308 |
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.2 | 0.456 | 22592563 |
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | qRT-PCR and SFA | NA | 0.2 | 0.0647 | 34246759 |
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0891 | 31658996 |
| ZNF322 | 23640 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA and qRT-PCR followed by Tumorigenicity assay | NA | 0.2 | 0.0011 | 30258097 |
| ALDH1A2 | 15472 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Pemetrexed | ALDEFLUOR assay | NA | 0.12 | 0.0117 | 26181204 |
| CD38- | 1667 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.12 | 0.0011 | 22592563 |
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | FACs followed by CFA | NA | 0.12 | 0.211 | 33550205 |
| EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | H460 | NA | SFA followed by FACs | NA | 0.12 | 0.211 | 22592563 |
| ANKRD37 | 29593 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 24961511 |
| ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 24961511 |
| APP | 620 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| APP | 620 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| APP | 620 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| APP | 620 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 24961511 |
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| C3 | 1318 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| C3 | 1318 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| CACNA2D3 | 15460 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CACNA2D3 | 15460 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 24961511 |
| CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 24961511 |
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CDH18 | 1757 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CDH18 | 1757 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CDH18 | 1757 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CDH18 | 1757 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CRIM1 | 2359 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CRIM1 | 2359 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CRIM1 | 2359 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CRIM1 | 2359 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| CTNNAL1 | 2512 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CTNNAL1 | 2512 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| CXCL14 | 10640 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CXCL14 | 10640 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CYP51A1 | 2649 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CYP51A1 | 2649 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CYP51A1 | 2649 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| CYP51A1 | 2649 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| DLC1 | 2897 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| DLC1 | 2897 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| EBP | 3133 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| EBP | 3133 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 24961511 |
| EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 24961511 |
| EGLN3 | 14661 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| EGLN3 | 14661 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |
| EGLN3 | 14661 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |
| ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 24961511 |
| ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 24961511 |
| FA2H | 21197 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| FA2H | 21197 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| FADS2 | 3575 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| FADS2 | 3575 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| FBLN1 | 3600 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| FBLN1 | 3600 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| FBN2 | 3604 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| FBN2 | 3604 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| FKBP10 | 18169 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| FKBP10 | 18169 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| FRAS1 | 19185 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| FRAS1 | 19185 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| GALNT16 | 23233 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| GALNT16 | 23233 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 24961511 |
| HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 24961511 |
| IDI1 | 5387 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| IDI1 | 5387 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| IFI30 | 5398 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| IFI30 | 5398 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 24961511 |
| IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 24961511 |
| IGFBP6 | 5475 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| IGFBP6 | 5475 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| IL21R | 6006 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| ITGA7 | 6143 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| ITGA7 | 6143 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| ITGA7 | 6143 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| ITGA7 | 6143 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| KCNIP3 | 15523 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| KCNIP3 | 15523 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| LAMA1 | 6481 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| LAMA1 | 6481 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| LSS | 6708 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| LSS | 6708 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| MYL5 | 7586 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| MYL5 | 7586 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| NOV | 7885 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| NOV | 7885 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 24961511 |
| NRXN3 | 8010 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| NRXN3 | 8010 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| NRXN3 | 8010 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| NRXN3 | 8010 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| PCDH20 | 14257 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| PCDH20 | 14257 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| PCDH20 | 14257 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| PCDH20 | 14257 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| PI3 | 8947 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| PI3 | 8947 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 24961511 |
| PLSCR4 | 16497 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| PLSCR4 | 16497 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| PRKCB | 9395 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| PRKCB | 9395 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 24961511 |
| SERPINB11 | 14221 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| SERPINB11 | 14221 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| SLC1A3 | 10941 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SLC1A3 | 10941 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SLC8A1 | 11068 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| SLC8A1 | 11068 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| SPINK1 | 11244 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| SPINK1 | 11244 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 24961511 |
| SPINK6 | 29486 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SPINK6 | 29486 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 24961511 |
| STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 24961511 |
| STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 24961511 |
| SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 24961511 |
| TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| THBS3 | 11787 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| THBS3 | 11787 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| THBS3 | 11787 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| THBS3 | 11787 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 24961511 |
| TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 24961511 |
| TM7SF2 | 11863 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |
| TM7SF2 | 11863 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |
| TM7SF2 | 11863 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |
| TM7SF2 | 11863 | HTM | Non Small Cell Lung Cancer | Carcinoma | H460 | Cisplatin | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 24961511 |